Cargando…

Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma

Purpose: Whether nutritional assessment and management improves clinical outcomes in patients with clinical T1N0M0 esophageal squamous cell carcinoma (ESCC) who undergo chemoradiotherapy remains to be demonstrated. This study aimed to determine the nutritional status of such patients pre- and post-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakanaka, Katsuyuki, Fujii, Kota, Ishida, Yuichi, Miyamoto, Shin’ichi, Horimatsu, Takahiro, Muto, Manabu, Mizowaki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497910/
https://www.ncbi.nlm.nih.gov/pubmed/31118785
http://dx.doi.org/10.2147/CMAR.S189518
_version_ 1783415559622230016
author Sakanaka, Katsuyuki
Fujii, Kota
Ishida, Yuichi
Miyamoto, Shin’ichi
Horimatsu, Takahiro
Muto, Manabu
Mizowaki, Takashi
author_facet Sakanaka, Katsuyuki
Fujii, Kota
Ishida, Yuichi
Miyamoto, Shin’ichi
Horimatsu, Takahiro
Muto, Manabu
Mizowaki, Takashi
author_sort Sakanaka, Katsuyuki
collection PubMed
description Purpose: Whether nutritional assessment and management improves clinical outcomes in patients with clinical T1N0M0 esophageal squamous cell carcinoma (ESCC) who undergo chemoradiotherapy remains to be demonstrated. This study aimed to determine the nutritional status of such patients pre- and post-chemoradiotherapy and its clinical outcomes. Patients and methods: This single institutional retrospective study included patients who underwent chemoradiotherapy for clinical T1N0M0 ESCC using serum albumin concentrations and body weights evaluated pre- and post-chemoradiotherapy from January 2005 to December 2016. The nutritional risk index (NRI) score was used to quantify the nutritional status: NRI score ≥100: no risk, 97.5–100: mild risk, 83.5–97.5: moderate risk, and <83.5: major risk. NRI categories pre-and post-chemoradiotherapy were compared using Wilcoxon signed rank test. Local-regional control (LRC), overall survival (OS), and cause-specific survival (CSS) rates were calculated using Kaplan–Meier method. The effect of pre-chemoradiotherapy NRI score and decreased NRI category during chemoradiotherapy on OS was evaluated using log-rank test. Results: Among the 492 patients with ESCC who underwent chemoradiotherapy, 44 were included in this study. Among these, 21 patients exhibited a pre-chemoradiotherapy NRI score of <100. During chemoradiotherapy, the NRI score decreased from 100.5 to 94.5, and the median NRI category significantly decreased by 2 (p<0.0001). With a median follow-up of 72 months, the 5-year LRC, OS, and CSS rates were 79.8%, 88.9%, and 96.8%, respectively. The pre-chemoradiotherapy NRI score of <100 and decreased NRI category during chemoradiotherapy did not significantly affect OS. Conclusion: Patients with clinical T1N0M0 ESCC without dysphagia were at risk of undernutrition pre- and post-chemoradiotherapy. The current study’s results justify further clinical nutritional research for this population, and that clinicians consider nutritional support for this population.
format Online
Article
Text
id pubmed-6497910
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-64979102019-05-22 Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma Sakanaka, Katsuyuki Fujii, Kota Ishida, Yuichi Miyamoto, Shin’ichi Horimatsu, Takahiro Muto, Manabu Mizowaki, Takashi Cancer Manag Res Original Research Purpose: Whether nutritional assessment and management improves clinical outcomes in patients with clinical T1N0M0 esophageal squamous cell carcinoma (ESCC) who undergo chemoradiotherapy remains to be demonstrated. This study aimed to determine the nutritional status of such patients pre- and post-chemoradiotherapy and its clinical outcomes. Patients and methods: This single institutional retrospective study included patients who underwent chemoradiotherapy for clinical T1N0M0 ESCC using serum albumin concentrations and body weights evaluated pre- and post-chemoradiotherapy from January 2005 to December 2016. The nutritional risk index (NRI) score was used to quantify the nutritional status: NRI score ≥100: no risk, 97.5–100: mild risk, 83.5–97.5: moderate risk, and <83.5: major risk. NRI categories pre-and post-chemoradiotherapy were compared using Wilcoxon signed rank test. Local-regional control (LRC), overall survival (OS), and cause-specific survival (CSS) rates were calculated using Kaplan–Meier method. The effect of pre-chemoradiotherapy NRI score and decreased NRI category during chemoradiotherapy on OS was evaluated using log-rank test. Results: Among the 492 patients with ESCC who underwent chemoradiotherapy, 44 were included in this study. Among these, 21 patients exhibited a pre-chemoradiotherapy NRI score of <100. During chemoradiotherapy, the NRI score decreased from 100.5 to 94.5, and the median NRI category significantly decreased by 2 (p<0.0001). With a median follow-up of 72 months, the 5-year LRC, OS, and CSS rates were 79.8%, 88.9%, and 96.8%, respectively. The pre-chemoradiotherapy NRI score of <100 and decreased NRI category during chemoradiotherapy did not significantly affect OS. Conclusion: Patients with clinical T1N0M0 ESCC without dysphagia were at risk of undernutrition pre- and post-chemoradiotherapy. The current study’s results justify further clinical nutritional research for this population, and that clinicians consider nutritional support for this population. Dove 2019-04-26 /pmc/articles/PMC6497910/ /pubmed/31118785 http://dx.doi.org/10.2147/CMAR.S189518 Text en © 2019 Sakanaka et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sakanaka, Katsuyuki
Fujii, Kota
Ishida, Yuichi
Miyamoto, Shin’ichi
Horimatsu, Takahiro
Muto, Manabu
Mizowaki, Takashi
Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma
title Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma
title_full Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma
title_fullStr Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma
title_full_unstemmed Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma
title_short Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma
title_sort nutritional and clinical outcomes of chemoradiotherapy for clinical t1n0m0 esophageal carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497910/
https://www.ncbi.nlm.nih.gov/pubmed/31118785
http://dx.doi.org/10.2147/CMAR.S189518
work_keys_str_mv AT sakanakakatsuyuki nutritionalandclinicaloutcomesofchemoradiotherapyforclinicalt1n0m0esophagealcarcinoma
AT fujiikota nutritionalandclinicaloutcomesofchemoradiotherapyforclinicalt1n0m0esophagealcarcinoma
AT ishidayuichi nutritionalandclinicaloutcomesofchemoradiotherapyforclinicalt1n0m0esophagealcarcinoma
AT miyamotoshinichi nutritionalandclinicaloutcomesofchemoradiotherapyforclinicalt1n0m0esophagealcarcinoma
AT horimatsutakahiro nutritionalandclinicaloutcomesofchemoradiotherapyforclinicalt1n0m0esophagealcarcinoma
AT mutomanabu nutritionalandclinicaloutcomesofchemoradiotherapyforclinicalt1n0m0esophagealcarcinoma
AT mizowakitakashi nutritionalandclinicaloutcomesofchemoradiotherapyforclinicalt1n0m0esophagealcarcinoma